11/06/2007
Data Showing that ReGen’s Colostrinin(TM) Supports Healthy Cognitive Function Presented at the 2007 International Congress on Natural Medicine in Australia
ReGen Therapeutics Plc (London, UK) is pleased to announce that a review of scientific and clinical information on Colostrinin(TM), its nutraceutical product which the Company believes has the potential to support healthy cognitive function, was presented today at the 2007 International Congress on Natural Medicine in Surfers Paradise, Queensland, Australia by Dr Marian Kruzel,
ReGen’s Chief Scientific Officer.
The conference, which is being attended by key opinion leaders and practitioners of natural medicine from around the world, is being sponsored by Metagenics Inc. of California via its Australian affiliate company Health World Ltd.
Metagenics have licensed the rights to Colostrinin(TM) for the North American market and intend to introduce it in the USA as a nutritional supplement during the last quarter of 2007.
Dr. Kruzel presented both pre-clinical and human clinical data showing that Colostrinin(TM):
- reduces the production of intracellular reactive oxygen species (ROS). These increase with old age and are associated with tissue and metabolic Damage
- prevents the aggregation of beta-amyloid and its consequent neurotoxicity. This is a protein associated with Alzheimer’s disease
- increases the lifespan of mice prone to premature ageing by around 30% when given in the drinking water
- is well-tolerated and without adverse effect when given to animals at doses up to 100 times that recommended for humans daily for prolonged periods
- had beneficial effects on the cognitive and functional performance of around 150 human subjects in clinical trials with mild to moderate Alzheimer’s disease.
Commenting after his presentation Dr. Kruzel said, ‘The audience here is extraordinary, it includes physicians, health care professionals and many other disciplines concerned about wellbeing in rapidly aging societies. It is a great pleasure to have the opportunity to present our cutting edge scientific research that validates the efficacy of nutraceutical strategies in the management of neurodegenerative diseases to such an audience’.
Jeff Katke, Chairman and Chief Executive Officer of Metagenics added, ‘As advocates of natural medicine we are very pleased to be close to introducing Colostrinin(TM) in the US as we see it as an important part of our science-based neurological product line and believe it will help to maintain the health of the ageing population. Today’s presentation by Dr Kruzel will be useful in
communicating the benefits of Colostrinin(TM) to a wider audience’.
For further information, please contact:
Andrew Marshall
Greycoat Communications
Tel: 020 7960 6007
Mobile No: 07785 297111
Rod Venables/Cecil Jordaan
HB Corporate
Tel: 020 7510 8600
Percy Lomax
ReGen Therapeutics Plc
Tel: 020 7153 4920